Winds From the ORIENT: New Data to Inform RATIONAL Choice?

Immune checkpoint inhibitors (ICIs), representing the current backbone of patients with nononcogene addicted, advanced disease and others, are rapidly changing the treatment landscape of NSCLC.1 Although PD-L1–positive tumors may be treated with PD-1 or PD-L1 inhibitors either as a single agent or in combination with chemotherapy or CTLA-4 inhibitors, those defined as having PD-L1 negative should receive chemoimmunotherapy as upfront standard of...